Menu Search
Equities

Sarepta Therapeutics Inc

SRPT:NSQ

Sarepta Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)114.23
  • Today's Change3.73 / 3.38%
  • Shares traded908.22k
  • 1 Year change+36.36%
  • Beta0.7280
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Sarepta Therapeutics Inc grew revenues 33.26% from 933.01m to 1.24bn while net income improved from a loss of 703.49m to a smaller loss of 535.98m.
Gross margin85.92%
Net profit margin7.43%
Operating margin4.79%
Return on assets3.63%
Return on equity12.27%
Return on investment4.38%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Sarepta Therapeutics Inc fell by 541.79m. Cash Flow from Financing totalled 125.00m or 10.05% of revenues. In addition the company used 500.99m for operations while cash used for investing totalled 165.80m.
Cash flow per share1.60
Price/Cash flow per share65.77
Book value per share12.79
Tangible book value per share12.50
More ▼

Balance sheet in USDView more

Sarepta Therapeutics Inc has a Debt to Total Capital ratio of 50.13%, a lower figure than the previous year's 161.80%.
Current ratio3.84
Quick ratio3.03
Total debt/total equity1.01
Total debt/total capital0.5013
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.